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Abstract: 
Viral infections that are often overlooked as common seasonal illnesses such as 
influenza can rapidly become a public threat. They threaten society as new, more 
dangerous strains of these common viruses emerge and as strains develop resistance 
to current vaccines and antiviral treatments (Kochanek, Murphy, Xu, & Tejada-Vera, 
2014). To combat this, the development of antiviral treatments with novel mechanisms 
of action is essential. Repurposing drugs instead of developing new drugs can save 
years of development time and hundreds of millions of dollars (DiMasi, Hansen, & 
Grabowski, 2003). To support the effort to discover drugs with unique mechanisms of 
action, a library of commercially available compounds was screened for antiviral activity. 
The compounds were tested against influenza A virus, enterovirus 068 (EV-068), 
respiratory syncytial virus (RSV), and parainfluenza virus (PIV). In addition, fluoxetine 
hydrochloride (Prozac®) was tested for activity against EV-068 as a proof-of-concept to 
verify our methodology and to support the idea that repurposed drugs may have 
antiviral activity with potential to function as effective treatments. 
Antiviral activity was tested using in vitro antiviral assays that measure virus-
induced cytopathic effect (CPE) in the presence of test compounds. CPE was measured 
by neutral red (NR) staining. Partial antiviral activity was observed for several 
compounds against influenza, and that activity was confirmed using a direct virus yield 
reduction assay (VYR) for multiple drug concentrations. However, no antiviral activity 
was observed for any of the compounds evaluated against EV-068, RSV, or PIV. The 
drugs with anti-influenza activity may have potential for further development into 
effective antiviral treatments. 
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Evaluating the Potential of Repurposing Commercially Available Drugs for the 
Treatment of Viral Infections 
Abstract: 
1 
Viral infections that are often overlooked as common seasonal illnesses such as 
influenza can rapidly become a public threat. They threaten society as new, more 
dangerous strains of these common viruses emerge and as strains develop resistance 
to current vaccines and antiviral treatments (Kochanek, Murphy, Xu, & Tejada-Vera, 
2014). To combat this, the development of antiviral treatments with novel mechanisms 
of action is essential. Repurposing drugs instead of developing new drugs can save 
years of development time and hundreds of millions of dollars (DiMasi, Hansen, & 
Grabowski, 2003). To support the effort to discover drugs with unique mechanisms of 
action, a library of commercially available compounds was screened for antiviral activity. 
The compounds were tested against influenza A virus, enterovirus D68 (EV-D68), 
respiratory syncytial virus (RSV), and parainfluenza virus (PIV). In addition, fluoxetine 
hydrochloride (Prozac®) was tested for activity against EV-D68 as a proof-of-concept to 
verify our methodology and to support the idea that repurposed drugs may have 
antiviral activity with potential to function as effective treatments. 
Antiviral activity was tested using in vitro antiviral assays that measure virus-
induced cytopathic effect (CPE) in the presence of test compounds. CPE was measured 
by neutral red (NR) staining. Partial antiviral activity was observed for several 
compounds against influenza, and that activity was confirmed using a direct virus yield 
reduction assay (VYR) for multiple drug concentrations. However, no antiviral activity 
was observed for any of the compounds evaluated against EV-D68, RSV, or PIV. The 
drugs with anti-influenza activity may have potential for further development into 
effective antiviral treatments. 
Introduction: 
New viruses are constantly emerging as public health threats, and known viruses 
are constantly evolving resistance to current antiviral drugs. It is important to continue 
developing and testing antiviral drugs with new mechanisms of action to keep up with 
ever-changing viruses. This study focused on two dangerous viruses that are often 
overlooked: influenza and enterovirus D68 (EV-D68) (Messacar et al., 2016). Influenza 
is currently among the top causes of death in America (Kochanek, Murphy, Xu, & 
Tejada-Vera, 2014). Historical and current strains of the virus have been known to have 
very high mortality and transmission rates (Dawood et al., 2012; Reid, Taubenberger, & 
Fanning, 2004). The H5N1 strain, often known as the "bird flu," is a recently emerged 
strain that causes mortality in more than half of those infected (Seigel et al., 2005). 
There are several vaccines and antiviral treatments available to prevent and treat 
influenza infections. However, influenza virus is subject to both antigenic shift and drift 
which help the virus evade immune responses, limiting the effectiveness of vaccines. In 
addition, influenza virus is able to develop resistance to antiviral therapies that are 
widely used through the same mechanisms. An important example is amantadine, an 
antiviral first reported in 1963 designed for use against influenza (Maugh, 1976). 
Circulating influenza strains have since become so resistant to amantadine that the 
CDC currently recommends against its use (Fiore et al., 2011 ). H1 N1 strains of 
influenza resistant to oseltamivir, a modern flu drug, have already been observed to be 
circulating at high frequency (Dharan et al., 2009). 
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The other focus virus of this study, EV-D68, is a recently emerging virus 
belonging to the Picornaviridae family, which also includes polio and rhinoviruses. EV-
D68 causes respiratory disease and is mainly symptomatic only in children (Oberste et 
al., 2004). It was not a subject of public concern until 2014, when there was an outbreak 
of EV-D68 with over 1000 reported cases of severe respiratory disease. In addition, in 
the U.S. alone, there were at least 100 reported cases of acute flaccid paralysis 
associated with EV-D68 with symptoms similar to paralytic poliomyelitis. Since this 
outbreak, additional cases have been reported worldwide. The CDC estimates that 
millions more were infected but did not develop symptoms severe enough to warrant 
testing for the virus. Currently there are no FDA-approved treatments or vaccines 
available for prevention or treatment of EV-D68 (Messacar et al., 2016). Several 
antivirals have demonstrated activity in vitro, but many of these compounds are still in 
the early stages of investigation (Smee, Evans, Nicolaou, Tarbet, & Day, 2016). Due to 
the stringent approval process of the FDA, it is important to continue to evaluate new 
compounds for activity against EV-D68 as none of these compounds are guaranteed to 
be approved for use in humans. 
To contribute to the development of new antiviral treatments for these viruses, 
test drugs were selected and tested in the course of this study under the rational of 
repurposing drugs for antiviral treatment. Developing new drugs is a costly in both 
money and time. Current estimates place those costs close to one billion dollars and 15 
years of development time to secure FDA approval for each new drug that reaches the 
market (DiMasi et al., 2003; DiMasi, Hansen, Grabowski, & Lasagna, 1991 ). 
Repurposing already approved drugs can be completed in about two years and saves 
approximately 40% of the cost of developing new drugs (Chong & Sullivan, 2007). Our 
prediction was that by testing a commercially available library of drugs, we might be 
able to find compounds with antiviral activity suitable for clinical treatment of viral 
infections or future development of more potent antiviral treatments. 
Beyond the cost-savings of repurposing drugs, another benefit of this strategy is 
that it allows the discovery of drugs with novel mechanisms of antiviral action to which 
viruses have not developed resistance. For example, a new anti-flu drug, Baloxavir 
marboxil (trade name Xofluza®), was approved in October 2018 (Hayden et al., 2018). 
Baloxivir functions by inhibiting the cap-snatching mechanism of the flu polymerase 
which is a novel mechanism of action among FDA-approved anti-flu therapies (Noshi et 
al., 2018). This compound is an excellent example of how compounds with novel 
mechanisms of action can be useful in fighting viral infections. 
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Methods 
To find compounds with potential to be repurposed to treat influenza and EV-D68 
infections, a commercially available chemical library containing many FDA-approved 
drugs was used as a starting point (TargetMol Fluorochemical Library, Catalog No. 
L5100). Due to a lack of resources, we were not able to screen all 586 compounds in 
the library. Therefore, the potential for antiviral activity of each compound was estimated 
based upon searches using Google Scholar and PubMed to find any data for each 
compound. From the library, a total of 33 compounds were selected for testing against 
influenza and EV-D68. According to compound availability, 14 compounds were also 
tested against respiratory syncytial virus (RSV) and parainfluenza virus (PIV). The full 
list of compounds and the rational for testing each one is displayed in Supplementary 
Table 1. 
Compounds were selected for testing because they previously demonstrated 
activity against other viruses or belonged to classes of compounds known to 
occasionally demonstrate antiviral activity, which could bring mechanisms of action 
previously unused in influenza and EV-D68 treatment to light. One class of compounds 
broadly selected for testing was protease inhibitors. When appropriately targeted to viral 
proteins, protease inhibitors block viral replication. Another broad class of drug tested in 
this experiment were drugs targeting membrane transporters or ion channels Though 
many of these compounds have known uses in neurology, they have also occasionally 
demonstrated antiviral activity. 
In addition to testing the library of drugs mentioned above, to validate our assays 
and the concept of repurposing drugs for use as antiviral treatments, the well-known 
antidepressant fluoxetine hydrochloride, better known as Prozac®, was evaluated for 
antiviral activity against EV-D68 and coxsackievirus B3 (COXV). The rationale for this 
was based on previous studies that demonstrated the in vitro activity of fluoxetine 
against EV-D68 and coxsackievirus B3 (Rhoden, Zhang, Nix, & Oberste, 2015a; Ulferts 
et al., 2013). Replicating these positive results also lends support to the idea that 
repurposed drugs can have antiviral activity. However, it is important to note that 
despite the effectiveness of fluoxetine in vitro, fluoxetine was not effective in animal 
models of EV-D68 infection (Hixon, Clarke, & Tyler, 2017). 
All viruses used in this study except for PIV were obtained from ATCC 
(Manassas, VA) and propagated in cell culture. The strains were influenza A H1 N1 
(A/California/07/2009, ATCC VR-1894), enterovirus D68 (US/KY/14-18953, ATCC VR-
1825), influenza A PR8 (A/PR/8/34 TC Adapted, ATCC VR-1825), respiratory syncytial 
virus strain A2 (ATCC VR-1540), and coxsackievirus B3 (ATCC VR-688). Parainfluenza 
virus type 3 strain 14702 was acquired from a clinical isolate (J. Bouvin, Hosp. St. 
Justine, Montreal, Canada). These viruses were propagated in cell culture to create 
virus stocks. The cell lines used in this study were MOCK (ATTC CCL-34), RD (ATTC 
CCL-136), MA-104 (ATTC CRL-2378.1), and Vero 76 (ATCC CRL-1587). 
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All drugs were tested using a primary cytopathic effect (CPE) reduction assay as 
described by Smee et al., 2016. Briefly, testing was completed by evaluating 4 log-
dilution concentrations of each compound in 96-well plates. At each concentration, 3 
wells of near-confluent cell cultures seeded the day previously were infected with virus 
and exposed to the test compound to measure the protection from virus-induced CPE 
offered by the compound. Further details of cell seeding and viral dose for each virus 
can be found in Table 1. Two uninfected wells were also tested at each drug 
concentration to determine the cytotoxicity of the compounds. Untreated cell controls 
and virus controls were also included on each plate. Positive control compounds with 
known antiviral activity were included with each test. 
Following viral incubation, neutral red was added to each well and the plates 
were incubated for two hours at 37°C. Neutral red is absorbed only by living cells. 
Following incubation, the wells were aspirated to remove neutral red and rinsed with 
PBS to ensure all unincorporated dye was removed, and an extraction buffer was added 
to solubilize the neutral red. The percentage of living cells in each well was estimated by 
comparing absorbance as measured at 540 nm by a spectrophotometer to that of 
untreated cell control wells. Virus-induced CPE was normalized to untreated virus 
control wells. The 50% effective (EC50, virus-inhibitory) concentrations and 50% 
cytotoxic (CC50, cell-inhibitory) concentrations were determined through linear 
regression on a Microsoft Excel spreadsheet. Dividing the CC50 values by the EC50 
values gives a selectivity index (SI) value, which is used to determine the antiviral 
efficacy of a compound. A higher SI value is indicative of increased antiviral activity and 
decreased cellular cytotoxicity. 
Additionally, the compounds that demonstrated activity against influenza were 
also tested by virus yield reduction (VYR) to determine the concentration at which 90% 
of active virus production was inhibited by the compound (EC90). For this test, 
compounds were tested at 8 half-log concentrations. Prior to neutral red staining, 
samples of supernatant were harvested from each drug concentration. These samples 
were evaluated for viral titer using an end-point dilution method and were calculated 
using the Reed-Muench method (Reed & Muench, 1938). The titers from each 
concentration of the compound were compared to the untreated virus control to 
determine viral load reduction, and EC90s were calculated by linear regression. 
Results: 
The rationale of this project was partially encouraged by the previous successful 
in vitro testing of fluoxetine against EV-D68 and coxsackievirus (Rhoden et al., 2015a; 
Ulferts et al., 2013; Zuo et al., 2012). As shown in Table 2, our results matched closely 
with the published results, which validated our in vitro testing methods. 
When tested against influenza A, several of the drugs demonstrated modest 
antiviral activity, as shown in Table 3. JNJ-42041935 appeared to have the most activity 
as measured by EC90, but its activity was still modest. Many of these drugs were also 
partially active against influenza PR8, as shown in Table 4. 
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All 33 compounds were evaluated against EV-D68, but no antiviral activity was 
observed. All anti-EV-D68 SI values were less than 2. Of those 33 compounds, 14 were 
tested against RSV and PIV, and none demonstrated activity against either virus {data 
in Supplementary Table 1 ). 
Discussion and Conclusions: 
The close agreement regarding the antiviral activity of fluoxetine between the 
published data and our measured results validated our ability to accurately measure 
antiviral activity in repurposed pharmaceuticals (Rhoden, Zhang, Nix, & Oberste, 2015b; 
Ulferts et al., 2013; Zuo et al., 2012). The confirmed evidence of fluoxetine's activity 
against EV-D68 supports the idea that pharms:1ceuticals designed for other purposes 
can have potential to be repurposed as antiviral treatments. 
Most of the compounds found in this study were not active against the viruses 
tested. By offering this information for publication, we hope to help other researchers 
avoid needlessly re-testing these compounds for antiviral activity. Many publications 
about new antiviral compounds often focus on a specific compound or set of 
compounds that are highly active. However, they occasionally include lists of other 
inactive compounds or strains .of virus that were resistant to the focus compound to 
avoid repetition (Kumaki et al., 2018; Smee, Evans, Nicolaou, Tarbet, & Day, 2016; 
Smee, Hurst, Day, & Geiben-Lynn, 2014). 
The compounds with the highest partial activity found in this study shown in 
Tables 2 and 3 are not active enough to be considered for immediate development as 
antiviral treatments. However, they may indicate a good starting point for the 
investigation and synthesis of new types of compounds. Normally SI values of greater 
than 10 are desirable to indicate noteworthy activity, but SI values of 4-9 can suggest 
partial activity. Determining the exact mechanism by which these compounds partially 
inhibit influenza may lead to development of stronger compounds with similar modes of 
action. The best way to continue this research would be to investigate the molecular 
mechanisms of the partially active drugs found in this study. For example, 5a-reductase 
inhibitors, a family of chemicals which include Dutasteride, one of the most active anti-
flu compounds in this study, were shown to be highly active against influenza in a 
previous study. (AI-Mohizea, Al-Omar, Abdalla, & Amr, 2012). By discovering their 
specific molecular mechanisms of action, some of the other compounds in this study 
could be developed into chemical families with similarly potent results. 
Another avenue to further pursue this research would be to continue to screen 
other compound libraries for FDA-approved drugs with potential to be repurposed as 
antiviral treatments. The major limitation of this study was that due to funding reasons, 
we were forced to screen a relatively narrow selection of drugs. Future studies could 
expand on our work by testing a greater variety of compounds for antiviral activity. 
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Table 1: Virus testing parameters. 
Virus Cells Cells per Well CCIDso per Days 
Well Incubated 
H1N1 Cali MOCK 60,000 63 3 
H1N1 PR8 MOCK 60,000 63 3 
EV-D68 RD 60,000 160 3 
RSV MA-104 40,000 41 4 
PIV MA-104 40,000 31 7 
H1 N1 (Cali) refers to influenza A/California/07/2009, and H1 N1 (PR8) refers to influenza 
A/PR/8/34 TC adapted. RSV and PIV refer to respiratory syncytial virus and 
parainfluenza virus, respectively. CCIDso is the 50% cell culture infectious dose- a dose 
of virions that will infect 50% of cell cultures on average. The CCIDso number for each 
virus is how many infectious doses each infected well received to ensure infection. 
Legend for Tables 2-4: EC50: 50% effective concentration; concentration at which 
50% of viral-induced cytopathic effect was prevented. CC50: 50% cytotoxic 
concentration; concentration where compound toxicity caused 50% cell death. SI: 
selective index; SI is found by dividing EC50 by CC50. Higher SI values indicate 
increased antiviral activity and decreased compound toxicity. 
Table 2: Comparing published fluoxetine antiviral activity with study measures. 
Measured Values µM Published Values µM 
Virus EC50 CC50 SI EC50 CC50 SI 
EV-D68 1.21±0.38 13.01±3.26 10.8 0.34-1.05 n/a n/a 
coxv 0.98 9.3 9.5 3.36+.47 28 8.3 
The published EV-D68 values are from Rhoden et al., 2015, and represent the range of 
EC50 values measured for 4 different strains of EV-D68. The Coxsackievirus values 
were obtained from Zuo et al., 2012. 
Table 3: Antiviral activity against Influenza A/California/07/2009 (H1 N1). 
EC50 CC50 SI EC90 SI BY VYR 
Dutasteride 26 ± 27 >125 ± 0 >4.8 69 ± 79 >1.8 
P22077 17 ± 9.2 52 ± 15 3.2 31 ± 16 1.7 
JNJ-42041935 40 ± 21 120 ± 12 2.9 22 ± 6.4 5.3 
AEBSF HCI 32 ± 25 >125 ± 0 >3.9 86 ± 55 >1.4 
Ribavirin 38 + 30 >4100 >109 170 + 8.6 >265 
EC50 and CC50 values are in µM. Ribavirin served as a positive control. EC50 and 
CC50 values were tested in four replicates. EC90 was tested in duplicate. 
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Table 4: Antiviral activity against TC-adapted Influenza A/PR/8/34 
EC50 CC50 SI EC90 SI BYVYR 
Dutasteride 31 ± 9.9 >125 ± 0 >4.0 28 ± 14 >4.5 
P22077 14 ± 7.3 29 ± 14 2.0 18 ± 4.9 1.6 
JNJ-42041935 120 ± 17 >125 ± 0 >1.1 37 ± 4.7 >3.4 
AEBSF HCI 27 ± 4.2 >125 ± 0 >4.6 34 ± 15 >3.7 
Ribavirin 13 + 5.2 >4100 281 15 ± 1.8 >283 
EC50 and CC50 values are in µM. Ribavirin served as a positive control. EC50 and 
CC50 values were tested in three replicates. EC90 was tested in duplicate. 
Supplementary Table 1: Antiviral activity of multiple FDA-approved or bioactive compounds against influenza virus (HlNl), 
respiratory syncytial virus (RSV), and parainfluenza virus (PIV). SI values are the 50% cytotoxic concentration divided by the 50% 
effective concentration. Higher SI values indicate higher antiviral activity and lowered cellular toxicity. 
Compound H1N1 H1N1 EV- RSV PIV FDA Target Testing Rationale 
Name and CAS (Cali) (PR8) D68 SI 51 Approval 
Number SI SI SI 
Dutasteride 4.8:j: 4t O* 0 0 Approved Reductase Similar compounds have high 
164656-23-9 inhibitor antiviral activity. (AI-Mohizea et al., 
2012) 
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AEBSF 3.9:j: 4.6t O* 0 0 N/A Serine Reported activity against RSV. (Van 
hydrochloride Protease der Gucht et al., 2017) 
30827-99-7 inhibitor 
P22077 3.2:j: 2t 1.2 0 0 N/A DUB Active against HIV-1. (Selz et al., 
1247819-59-5 inhibitor 2017) 
Ketanserin 3 0 0 0 0 Approved 5-HT Active against JCV. (Nukuzuma, 
74050-98-9 Receptor Nakamichi, Nukuzuma, & 
antaaonist Takeaami, 2009) 
JNJ-42041935 2.9:j: 1.1 t 0.8* 0 0 N/A HIF/HIF Protease inhibitor. 
1193383-09-3 Prolyl-
Hydroxylase 
Odanacatib 2.7* nt 0 nt nt Approved Cysteine Protease inhibitor. 
(MK-0822) Protease 
603139-19-1 inhibitor 
Trelagliptin 2.4* nt 0 nt nt Approved DPP04 Protease inhibitor. 
865759-25-7 inhibitor 
PMSF 2.4* nt 0 nt nt N/A Multiple Protease inhibitor. 
329-98-6 Protease 
inhibitor 




Compound H1N1 H1N1 EV- RSV PIV FDA Target Testing Rationale 
Name and CAS (Cali) (PR8) D68 SI SI Approval 
Number SI SI SI 
MK3102 2.2* nt 0 nt nt Approved DPP-4 Protease inhibitor. 
1226781-44-7 inhibitor 
Dolutegravir 2* nt 0 nt nt Approved lntegrase Protease inhibitor. 
sodium inhibitor 
1051375-19-9 
Paliperidone 1.9* nt 0 nt nt Approved Neurogenic In silica evidence of antiviral 
144598-75-4 antagonist activity. (Patel & Kukol, 2017) 
Alvelestat 1.7t 0 0* 0 0 Clinical Serine Protease inhibitor. 
(AZD9668) Trials Protease 
848141-11-7 inhibitor 
IU1 1.5* nt 0 nt nt N/A DUB Active against Dengue virus and 
314245-33-5 inhibitor against other flaviviruses. (Nag & 
Finlev, 2012) 
PD 151746 1.5* nt 0 nt nt N/A Cysteine In silica evidence of antiviral 
179461-52-0 protease activity. (Byler, Collins, Ogungbe, & 
inhibitor Setzer, 2016) 
Z-FA-FMK 1.4* nt 0 nt nt N/A Cysteine Active against reoviruses. (Kim et 
197855-65-5 Protease al., 2010) 
inhibitor 
Flufenamic acid 1.4 4 0 0 0 Approved cox Active against influenza and 
530-78-9 inhibitor encephalomyocarditis. (Chan et al., 
2013; lnqlot, 1969) 
Danoprevir 1.3* nt 0 nt nt Clinical HCV Protease inhibitor 
(ITMN-191) Trials Protease 
8508-76-88-9 inhibitor 
Sitagliptin 1.2* nt 0 nt nt Approved DPP-4 Protease inhibitor 
486460-32-6 inhibitor 




Compound H1N1 H1N1 EV- RSV PIV FDA Target Testing Rationale 
Name and CAS (Cali) (PR8) D68 SI SI Approval 
Number SI SI SI 




Tiplaxtinin 0* nt 0 nt nt Clinical PAI inhibitor Active against rhabdoviruses. 
(PAl-039) Trials (Estepa & Coll, 2015) 
393105-53-8 
DAPT (GSI-IX) 0* nt 0 nt nt Clinical Gamma- Protease inhibitor 
208255-80-5 Trials secretase 
inhibitor 
LY411575 0* nt 0 nt nt NIA Gamma- Active against Hepatitis C. 
209984-57-6 secretase (Otoguro, Tanaka, Kasai, 
inhibitor Yamashita, & Moriishi, 2016) 
Lomerizine 0* nt 1.1 nt nt Approved Calcium Active against JEV and Hepatitis B. 
hydrochloride Channel (van de Klundert, Zaaijer, & 
101477-54-7 inhibitor Kootstra, 2016; Wanq et al., 2017) 
Teriflunomide 0* nt 0 nt nt Approved De hydrogen Active against TMEV. (Gilli, Li, 
108605-62-5 ase inhibitor Rovce, DiSano, & Pachner, 2017) 
Mosapride 0* nt 0 nt nt Approved 5-HT Neurological drug. 
Citrate Receptor 
112885-42-4 aqonist 
Leflunomide 0 0 1.7 2.1 0 Approved Protein- Active against EV-71, CMV, and 
75706-12-6 tyrosine HPV. (Hung, Shih, Chang, Fang, & 






Compound H1N1 H1N1 EV- RSV PIV FDA Target Testing Rationale 
Name and CAS (Cali) (PR8) D68 SI SI Approval 
Number SI SI SI 
Trifluoperazine 0 0 0 0 0 Approved Neurological Active against Influenza and 
di hydrochloride targets. Epstein-Barr. (Nemerow & Cooper, 
440-17-5 1984; Ochiai, Kurokawa, & 
Niwavama, 1991) 
Mefloquine 0 0 0 0 0 Approved Hemozoin Active against multiple viruses. 
hydrochloride synthesis (Brickelmaier et al., 2009) 
51773-92-3 inhibitor 
Flupenthixol 0 0 0 0 0 Approved Dopamine Active against HSV-22. 
dihydrochloride Receptor (Kristiansen, Andersen, 
51529-01-2 antaqonist Vesteraaard, & Hvidbera, 1991) 
Spiperone 0 0 0 0 0 Approved Dopamine Active against several 
749-02-0 Receptor polyamaviruses.(Goodwin, Atwood, 
antaqonist & DiMaio, 2009) 
Triflupromazine 0 0 0 0 0 Approved Neurogenic Active against MERS, SARS, and 
hydrochloride antagonist HSV-1. (Dyall et al., 2014; Purohit 
1098-60-8 et al., 2012) 
H1 N1 (Cali) refers to influenza A/California/07/2009, and H1 N1 (PR8) refers to influenza A/PR/8/34 TC adapted. 
Compounds were tested with different numbers of replicates against each virus according to compound availability and 
according to the activity observed in first and second replicate activity of each compound. nt: Not tested. *2 replicates. t3 
replicates. :j:4 replicates. Numbers with no notation had 1 replicate assay. 
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Reflective Writing 
After dozens of hours spent using pipettors, microscopes, spreadsheets and 
databases, I finally found the end results of all my hard work: that none of the 
compounds I had spent so much time and effort researching, selecting, and testing 
were active enough to make a real difference in the world or even to be published in a 
professional journal. However, I also found something else: that I genuinely enjoy 
research and that I feel that asking and answering questions has intrinsic value even 
when the results are unremarkable. To me personally, that result was worth all the 
effort. 
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This research project has been an incredible experience for me as a biology 
student and taught me many important lessons about what a career in research might 
be like. This is especially important to me as pursuing a research career remains my 
current plan for the future. The most important things that I've gained from this project 
have been learning about my own motivations, increasing and understanding my work 
ethic, and an opportunity for growth as a scientist, none of which are things I could have 
learned in a classroom. 
Regarding my motivations, I've discovered more about what kind of questions I'm 
interested in answering as a scientist. I've found that the more specific the question, the 
more interested I am in it. I'm interested in deeply looking into small details rather than 
trying to find shallow answers for many questions. Unfortunately, I've made that 
discovery because of the relatively shallow nature of this project. I've taken many 
compounds with minimal evidence of possible antiviral activity and tested them against 
a panel of viruses to see if they worked. As the project has progressed, I've become 
more interested in finding out why the compounds that have showed some measure of 
activity have worked. What are they binding to in the virus or the cell that is inhibiting 
viral replication? Is it possible to refine the chemical structure of these compounds to 
have a stronger antiviral effect? Could the compound work in animals or even humans? 
In the future, I'd consider large-scale screening like what I've done for this project as 
more of a preliminary step to more specific and interesting questions. 
Even though I'd prefer to work with more specific questions, another important 
thing I've learned through this project is that I can push through stalls, delays, and 
mistakes in the course of a project. This has been by far the largest project I've ever 
worked on, and has required an incredible amount of work to complete. Oftentimes the 
parts that required the most grit and determination were parts of the project that I didn't 
think would be very difficult or take a long time, only to see them balloon into formidable 
challenges. Taking this project to completion taught me what it feels like to approach a 
difficult problem, and step by step whittle it into manageable chunks until the whole 
things is done. I've also learned a lot about what it's like to work with a committee and 
professors, who though concerned and caring, are very busy. I've found that this type of 
committee work is not like turning in a test or an assignment in a normal class - it 
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requires a lot more coordination and teamwork with them to make sure things get done 
on a reasonable schedule. 
Finally, this project taught me a lot of specific lessons about what it will take to 
become a full-blown research scientist. One thing that I quickly realized that I did not 
know as much about as I thought I did was the importance and power of organization. 
Simple things like writing everything down and keeping all your files and information in 
as few places as possible that now seem obvious were not part of my workflow when I 
started this project. Though I'm sure I had been taught those things in lab classes and in 
other places, the tough teacher of experience was what really convinced me that these 
things are actually important. This project has also taught me a lot about the power of 
planning experiments well. As a biologist, many of our experiments are dependent on 
the growth and progress of organisms at a time scale we can't control and can only plan 
around. The longer this project went on, the better I got at planning individual 
experiments to work on a timeframe that worked well for me. Also, I learned that the 
more time spent time planning and preparing for an experiment, the more smoothly it 
would go. For example, I found that if I spent time the day before an experiment labeling 
all of the sample containers and plates and rounding up supplies, things would go ten 
times more smoothly than if I had tried to do that all on the same day as when I actually 
ran the experiment. 
Another important lesson this project taught me about being a scientist was how 
to deal with mediocre results through no fault of your own. Beyond dealing with 
disappointment and waning motivation to continue testing in a project where the 
preliminary results weren't too exciting, it also showed me how to adapt to the results 
you get. For example, if I was to continue in this project, I'd be enthusiastic to 
investigate the moderately active anti-flu compounds that I found to see why they work, 
which would likely be critical if this was a doctoral-level thesis or a major grant project. 
Beyond teaching me skills I could use as a future scientist, this project also has 
directly helped me with my future career as a scientist. I recently accepted an invitation 
to study in Dartmouth College's Molecular and Cellular Biology doctoral program. I have 
no doubt that being able to talk about how I largely independently planned, executed, 
and reported a large project like this helped to demonstrate my work ethic and growing 
skills as a scientist. 
Though the compounds I found in this study aren't ready to be used to treat viral 
infections, I hope that what I learned in the processes of testing them can make a 
difference in the world. My motivation to become a research biologist is a genuine hope 
that I can use my talents to help out people. Everyone you and I know has had their life 
touched by vaccines, pharmaceuticals, and medical science. My hope is that I too can 
learn to ask and answer the kinds of questions that led to these discoveries that will 
improve people's lives across the world. 
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